
**CLAIMS**


1. A pharmaceutical composition comprising

   a) 0.5-100 mg EGF(A) derivative, wherein the EGF(A) derivative is selected from the group of EGF(A) derivatives; # 31, 95, 128, 133, 143, 144, 150, 151, 152 and 153 with the following structures:


**31**




**95**




**128**




**133**




**143**




**144**




**150**



**151**




**152**



and

**153**



b) 20-1000 mg, such as 50-600 mg, of a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and

wherein said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid constitutes at least 90 w/w %, such as at least 95 w/w % of the excipients of the composition.

2. The pharmaceutical composition according to claim 1, wherein the composition comprises a lubricant, such as magnesium stearate or glyceryl dibehenate.


3. The pharmaceutical composition according to claim 1 or claim 2 consisting of:
   a) an EGF(A) derivative
   b) a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and
   c) at least one lubricant.

4. The pharmaceutical composition according to any of the previous claims, wherein said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid constitutes at least 70 w/w % of the composition.


5. The pharmaceutical composition according to any of the previous claims, wherein the compositions comprises 1-10 mg magnesium stearate per 100 mg of said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid.

~~6. The pharmaceutical composition according to any of the previous claims wherein the EGF(A) derivative is selected from the group of EGF(A) derivatives; # 31, 95, 128, 133, 143, 144, 150, 151, 152 and 153 with the following structures:~~


~~31~~




~~95~~




~~128~~




~~133~~




~~143~~




~~144~~




~~150~~



~~151~~




~~152~~




and

~~153~~



~~7.~~6. The pharmaceutical composition according to any of the previous claims, wherein the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid is sodium N-(8-(2-hydroxybenzoyl)amino)caprylate (SNAC).

~~8.~~7. The pharmaceutical composition according to any of the previous claims, wherein the EGF(A) derivative is



~~9.~~8. The pharmaceutical composition according to any of the previous claims, wherein a dose unit comprises;

a) 5-100 mg of the EGF(A) derivative,

b) 50-1000 mg of SNAC and

c) 0.5-50 mg lubricant.

~~10.~~9. The pharmaceutical composition according to any of the previous claims, wherein a dose unit comprises;

a) 5-100 mg of the EGF(A) derivative,

b) 100-800 mg of SNAC and


c) 1-40 mg magnesium stearate.

~~11.~~10. ~~The~~ A pharmaceutical composition ~~according to claim 8~~, wherein a dose unit comprises;

a) 20-100 mg of the EGF(A) derivative,

b) 100-600 mg of SNAC and

c) 1-30 mg lubricant, wherein the EGF(A) derivative is



.

~~12.~~11. The pharmaceutical composition according to claim ~~8~~ 10, wherein a dose unit comprises;

a) 20-100 mg of the EGF(A) derivative,

b) 100-600 mg of SNAC and

c) ~~1-25 mg, such as~~ 1-10 mg, such as 2-5 mg or such as 2-3 mg magnesium stearate per 100 mg ~~salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid~~ SNAC.

~~13.~~12. The pharmaceutical composition according to any of the previous claims, wherein the composition is a solid composition, such as a tablet, for oral administration.

~~14.~~13. A pharmaceutical composition according to any of the previous claims for use in medicine.

~~15.~~14. A pharmaceutical composition according to any of the previous claims for use in ~~a method of~~ i) improving lipid parameters and/or (ii) preventing and/or treating cardiovascular diseases.